Condition: Multiple Myeloma · Sponsor: Pfizer
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superior clinical benefit compared with the combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in people with newly diagnosed multiple myeloma. There are 2 parts to this study. Part 1 will characterize the safety and tolerability of elranatamab in combination with daratumumab and lenalidomide or in combination with lenalidomide and will identify the optimal dose(s) of the combination regimen. Part 2 of the study will evaluate the rate of minimal residual disease (MRD) negative CR and the progression free survival (PFS) of the combination of elranatamab, daratumumab, and lenalidomide compared with the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants with newly diagnosed multiple myeloma.
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| Jupiter Medical Center/Anderson Family Cancer Institute | Jupiter, Florida, United States | Not Yet Recruiting |
| MSK Basking Ridge | Basking Ridge, New Jersey, United States | Recruiting |
| MSK Monmouth | Middletown, New Jersey, United States | Recruiting |
| MSK Bergen | Montvale, New Jersey, United States | Recruiting |
| MSK Commack | Commack, New York, United States | Recruiting |
| MSK Westchester | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center-Main Campus | New York, New York, United States | Recruiting |
| MSK Nassau | Uniondale, New York, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Pindara Private Hospital | Benowa, Queensland, Australia | Recruiting |
| St Vincent's Hospital Melbourne | Fitzroy, Victoria, Australia | Recruiting |
+ 115 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05623020